Bernardsville, NJ, United States of America

Clive Arthur Arculus-Meanwell

This inventor holds 8 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: Chiesi Farmaceutici S.p.a., The Medicines Company. Active years: 2014-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Clive Arthur Arculus-Meanwell. Retrieved from https://idiyas.com/inventor/clive-arthur-arculus-meanwell

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8 (Patent Applications = 5)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 2.9

ph-index = 4

Forward Citations = 53(Granted Patents)

Location History:

Bernaardsville, NJ (US) (2021)
Bernardsville, NJ (US) (2014 - 2023)

Company Filing History:

5 out of 343

Chiesi Farmaceutici S.p.a.

patents

3 out of 26

The Medicines Company

patents

Years Active: 2014-2023

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11633419 - Methods of treating, reducing the incidence of, and/or preventing ischemic events (2023-04-25),

2. 11351187 - Methods of treating, reducing the incidence of, and/or preventing ischemic events (2022-06-07),

3. 11147879 - Methods of treating or preventing stent thrombosis (2021-10-19),

4. 10376532 - Methods of treating, reducing the incidence of, and/or preventing ischemic events (2019-08-13),

5. 9925265 - Methods of treating or preventing stent thrombosis (2018-03-27),

6. 9427448 - Methods of treating, reducing the incidence of, and/or preventing ischemic events (2016-08-30),

7. 8759316 - Maintenance of platelet inhibition during antiplatelet therapy (2014-06-24),

8. 8680052 - Methods of treating, reducing the incidence of, and/or preventing ischemic events (2014-03-25),

Title: Clive Arthur Arculus-Meanwell: Innovator in Ischemic Event Prevention

Introduction

Clive Arthur Arculus-Meanwell is a notable inventor based in Bernardsville, NJ (US). He has made significant contributions to the field of medicine, particularly in the prevention and treatment of ischemic events. With a total of 8 patents to his name, his work has the potential to impact patient care significantly.

Latest Patents

Arculus-Meanwell's latest patents focus on methods for treating, reducing the incidence of, and preventing ischemic events in patients undergoing percutaneous coronary intervention (PCI). One of his key inventions involves a pharmaceutical composition comprising cangrelor, which may be administered alongside additional therapeutic agents such as bivalirudin or a P2Y inhibitor. His patents also detail methods for preparing these pharmaceutical compositions, emphasizing the importance of cangrelor in preventing serious complications like stent thrombosis and myocardial infarction.

Career Highlights

Throughout his career, Arculus-Meanwell has worked with prominent companies in the pharmaceutical industry, including Chiesi Farmaceutici S.p.a. and The Medicines Company. His expertise in developing innovative treatments has positioned him as a valuable asset in the medical field.

Collaborations

Arculus-Meanwell has collaborated with notable professionals such as Simona Skerjanec and Jayne Prats, contributing to the advancement of medical treatments and research.

Conclusion

Clive Arthur Arculus-Meanwell's innovative work in the prevention and treatment of ischemic events showcases his dedication to improving patient outcomes. His patents and collaborations reflect a commitment to advancing medical science and enhancing therapeutic options for patients.

Profile summary based on public USPTO records.